Telos Corp (TLS) Q4 2025 Earnings Call Transcript

Why It Matters

The results validate TriSalus’ commercial strategy and provide runway to capture a $2.3 billion U.S. embolization market, positioning the firm for accelerated growth in 2026 and beyond.

Key Takeaways

• Q4 revenue $13.2M, 60% YoY growth.
• Gross margin rose to 87% quarter.
• Adjusted EBITDA loss narrowed to $0.95M.
• $46M equity raise strengthens cash position.
• Portfolio expanding to seven PEDD products by 2026.

Pulse Analysis

TriSalus Life Sciences leveraged a robust product rollout and disciplined cost management to deliver a 60% revenue surge in Q4 2025, outpacing many peers in the interventional radiology space. The uplift in gross margin to 87% reflects higher manufacturing efficiency and the premium pricing power of its pressure‑enabled drug delivery (PEDD) platform. Coupled with a dramatic reduction in adjusted EBITDA loss, the financials underscore a transition from loss‑making growth to a more sustainable operating model, reinforced by a $46 million equity infusion that lifts total cash reserves above $66 million.

The company’s aggressive commercial expansion—virtually doubling its sales footprint—and the diversification of its product suite are central to its growth narrative. Moving from two core offerings in 2025 to seven by 2026, TriSalus now addresses liver, thyroid, uterine, and genicular artery embolization, positioning itself as a one‑stop solution for interventional radiologists. Recent launches such as TriNav Flex and TriNet XP have garnered strong KOL endorsement for trackability and procedural efficiency, while the upcoming TriNet Advance, pending 510(k) clearance, promises to broaden market penetration further. This pipeline depth not only drives higher per‑account procedure volumes but also reduces sales complexity, enabling the expanded sales team to capture more market share.

Regulatory and reimbursement developments amplify the commercial upside. The introduction of CMS HCPCS code C8004 effectively doubled reimbursable use of the TriNet system for simulation and mapping, accelerating adoption across radioembolization workflows. With a $480 million addressable market for liver embolization and a broader $2.3 billion opportunity across all embolization indications, the reaffirmed $60‑62 million 2026 revenue guidance appears attainable. Early PROTECT registry results further validate clinical efficacy in thyroid applications, opening new patient segments. Together, these factors suggest TriSalus is well‑positioned to capitalize on a rapidly expanding market and deliver sustained revenue growth beyond 2026.